Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
List view / Grid view
Filter the results
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
International collaboration has shown that compounds with metals in them show antibacterial activity against MRSA, E. coli and A. baumannii.
Research has shown that leaky gut, the break down of gut lining junctions, could be targeted to reduce inflammation using metformin using an organoid model.
Drugs that were being developed to treat enterovirus have also been found to treat certain cancers in mice.
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.